Search

Memorial Sloan Kettering Cancer Center announced it has selected Epic to provide a new platform for integrated care that will ensure patients and physicians can more easily access electronic health records.

… Monday, November 21, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced it has selected Epic to provide a new platform for integrated care that will ensure patients and physicians can more easily access electronic health records (EHR). Implementing Epic is an important milestone that will

Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin®), a drug previously shown to improve outcomes in advanced cancer and prevent the return of cancer in women diagnosed with higher-risk, early-stage, HER2-positive breast cancer. This study appears online in the journal Cancer, and will be published in a future print edition.

… Friday, June 24, 2011 Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2 -positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin ® ), a drug previously shown to improve outcomes in advanced

The United States Preventive Services Task Force released updated draft recommendations on colorectal cancer screening which, among other things, call for screening for the general population to begin at age 45.

… Tuesday, October 27, 2020 The United States Preventive Services Task Force released updated draft recommendations on colorectal cancer screening which, among other things, call for screening for the general population to begin at age 45.  Currently the recommendations for those at average risk for the

Recently developed targeted drugs used to treat lung cancer are only partially effective. Scientists now know why.

… Wednesday, January 8, 2020 Summary Scientists at Memorial Sloan Kettering have discovered why certain drugs used to treat lung cancer are only partially effective. The findings point to combination therapies that might overcome this limitation. Among cancer biologists, finding a drug that can target

近期开发的用于治疗肺癌的靶向药物只是部分有效。而如今科学家发现了其中的原因。

… Wednesday, January 8, 2020 总结 纪念斯隆凯特琳癌症中心的科学家发现了为什么某些用于治疗 肺癌 的药物只是部分有效。研究结果表明，联合疗法也许能克服这一局限性。 对于癌症生物学家而言，他们一直致力于找到一种能靶向 KRAS 蛋白的药物。 KRAS 是癌症中最常见的突变蛋白之一，但直到最近人们还认为它基本上是不可药物治疗的——近乎球形的结构使其成为一个非常光滑的靶点。但在过去的几年中，科学家已发现用于阻止一种特定 KRAS 突变（KRAS G12C）的方法。蛋白质在“启动”和“关闭”之间循环，产生细微的形状变化，使得被称为 KRAS G12C 抑制剂的药物能够与之结合并使其失效

Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.

… Tuesday, March 5, 2013 Memorial Sloan Kettering Cancer Center announces the following appointments: Anas Younes, MD , has been named Chief of the Lymphoma Service in the Division of Hematologic Oncology, Department of Medicine. An internationally recognized medical oncologist with more than two decades

Researchers clarify how the immune system activates an inflammatory defense against pathogens.

… Thursday, April 18, 2019 Summary Pyroptosis is a form of inflammatory cell death launched by protein complexes called inflammasomes. Scientists have identified how an inflammasome called NLRP1B activates pyroptosis in immune cells to defend against anthrax infection. This sheds light on an important

Results from our recent retrospective study show that surgically managed patients with kidney cancer and comorbid mild to moderate chronic kidney disease (CKD) experience significantly less need for future dialysis.

… Monday, October 12, 2020 Results from our recent retrospective study show that surgically managed patients with kidney cancer and comorbid mild to moderate chronic kidney disease (CKD) experience significantly less need for future dialysis. The findings underscore the importance of careful patient selection

Surgical paradigm shifts to achieve complete cytoreduction during primary debulking surgery combined with the use of perioperative epidural anesthesia improve survival outcomes for ovarian cancer patients, our recently published research shows.

… Monday, October 8, 2018 Surgical paradigm shifts to achieve complete cytoreduction during primary debulking surgery and the use of perioperative epidural anesthesia improve survival outcomes for ovarian cancer patients, our recently published research shows. We collected data for all patients with stage

Learn more about HPV and cancer risk in the Hispanic community, which has more cancers linked to the disease than any other group in the United States.

… Tuesday, February 19, 2019 The vaccine against the human papillomavirus (HPV) has proven to be a remarkably potent weapon for preventing several kinds of cancer. But experts believe that far too few people are getting the vaccine. That leaves many people exposed to cancers that could be prevented. This